Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
The Associated Press on MSN5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
Some people who took a new schizophrenia drug for one year improved with only a few side effects, but many dropped out of the ...
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Bristol Myers Squibb (NYSE:BMY) said its newly approved schizophrenia therapy, Cobenfy, improved disease symptoms with a well ...
Tackling Schizophrenia
These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
Multiple studies have demonstrated people with established schizophrenia have an increased dopamine synthesis capacity, and ...
ABC News5d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
people lost a few pounds while taking Cobenfy, made by Bristol Myers Squibb. Dr. John Krystal of Yale University has led research on other schizophrenia drugs but was not involved in the new ...